PFE vs SNY
Pfizer and Sanofi, both Healthcare
Pfizer is the larger company at $144B against $101B. Over the past year PFE returned +24% against +1.1% for SNY. Ryufin's sector-relative Smart Score puts SNY ahead, 9/10 against 7/10.
| Figure | PFE | SNY |
|---|---|---|
| Last close | $28.32 | $45.44 |
| Market cap | $144B | $101B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 37.3 | n/a |
| Dividend yield | 6.1% | n/a |
| 1-year return | +24% | +1.1% |
| 5-year return | -15% | +9.1% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Pfizer
Revenue of $15B in Q2 2026, net income null. Its largest reported line is Eliquis, 15% of the disclosed total.
Sanofi
Revenue of $24B in H2 2025, net income $2.0B.
Open these two in the interactive comparison to add more names, change the period or read the correlation.